[On Demand]
Gero is the next-gen AI drug discovery company utilizing real-world big clinical, genetic (WES), and molecular data from vast human cohorts instead of animal models to help our partners create revolutionary medicines against complex diseases.

According to the research, the genetic link between target and disease increases the chances of passing the Phase II clinical trial almost twice. At Gero, we know how to do drug discovery from Whole-Exome Sequencing data to rapidly discover novel targets in human data and improve clinical trial success much more than that.

We are able to aggregate the effects of multiple rare mutations on the level of biological processes and pathways and give you multiple choices of interventions with the required effect.

We identify cause and effect relationships between mutations, disease progression models, targets, and drugs related to them.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
In-house immuno-senolytic discovered by AI in human data
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Gero PTE. LTD.